Stockreport
Allogene Therapeutics Announces Q2 Investor Conference Participation
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four investor conferences in the second quarter of 2024. Canaccord Genuity Horizons in Oncology Virtual ConferenceMonday, April 15, 202412:00pm PT/3:00pm ET JPM Securities Life Sciences Conference Tuesday, May 14, 20246:00am PT/9:00am ET 2024 RBC Capital Markets Global Healthcare Conference Wednesday, May 15, 20248:00am PT/11:00am ET Goldman Sachs 45th Annual Healthcare Conference Tuesday, June 11, 20245:40am PT/8:40am ET Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days. About Allogene Therapeutic
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | ALLO | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
ALLO alerts
ALLO alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
NEWS
NEWS
- Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma [Yahoo! Finance][Yahoo! Finance]
- Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma[GlobeNewswire]
- Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance][Yahoo! Finance]
- CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight [Yahoo! Finance][Yahoo! Finance]
- We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully [Yahoo! Finance][Yahoo! Finance]
- More
ALLO
SEC Filings
SEC Filings
- 4/26/24 - Form EFFECT
- 4/24/24 - Form 4
- 4/23/24 - Form ARS
- ALLO's page on the SEC website
- More